Search

Your search keyword '"Andersen, Mads Hald"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Andersen, Mads Hald" Remove constraint Author: "Andersen, Mads Hald" Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
49 results on '"Andersen, Mads Hald"'

Search Results

1. Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

2. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

3. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

4. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

5. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

6. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

7. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

8. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

9. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

10. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

11. Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

12. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

13. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

14. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

15. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

16. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

17. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

18. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

19. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

20. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

21. Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

22. Supplementary Methods from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

32. IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status

33. Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade

34. MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells

37. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling

38. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

40. Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase

49. Immunogenicity of Constitutively Active V599EBRaf

Catalog

Books, media, physical & digital resources